The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma

Klaus Podar, Giovanni Tonon, Martin Sattler, Yu Tsu Tai, Steven LeGouill, Hiroshi Yasui, Kenji Ishitsuka, Shaji K Kumar, Rakesh Kumar, Lini N. Pandite, Teru Hideshima, Dharminder Chauhan, Kenneth C. Anderson

Research output: Contribution to journalArticle

170 Citations (Scopus)

Abstract

A critical role for vascular endothelial factor (VEGF) has been demonstrated in multiple myeloma (MM) pathogenesis. Here, we characterized the effect of the small-molecule VEGF receptor inhibitor pazopanib on MM cells in the bone marrow milieu. Pazopanib inhibits VEGF-triggered signaling pathways in both tumor and endothelial cells, thereby blocking in vitro MM cell growth, survival, and migration, and inhibits VEGF-induced up-regulation of adhesion molecules on both endothelial and tumor cells, thereby abrogating endothelial cell-MM cell binding and associated cell proliferation. We show that pazopanib is the first-in-class VEGF receptor inhibitor to inhibit in vivo tumor cell growth associated with increased MM cell apoptosis, decreased angiogenesis, and prolonged survival in a mouse xenograft model of human MM. Low-dose pazopanib demonstrates synergistic cytotoxicity with conventional (melphalan) and novel (bortezomib and immunomodulatory drugs) therapies. Finally, gene expression and signaling network analysis show transcriptional changes of several cancer-related genes, in particular c-Myc. Using siRNA, we confirm the role of c-Myc in VEGF production and secretion, as well as angiogenasis. These preclinical studies provide the rationale for clinical evaluation of pazopanib, alone and in combination with conventional and novel therapies, to increase efficacy, overcome drug resistance, reduce toxicity, and improve patient outcome in MM.

Original languageEnglish (US)
Pages (from-to)19478-19483
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume103
Issue number51
DOIs
StatePublished - Dec 19 2006

Fingerprint

Vascular Endothelial Growth Factor Receptor
Multiple Myeloma
Endothelial Cells
Vascular Endothelial Growth Factor A
Neoplasms
Melphalan
Immunomodulation
Neoplasm Genes
Growth
pazopanib
Drug Resistance
Heterografts
Bone Marrow Cells
Small Interfering RNA
Cell Movement
Cell Survival
Up-Regulation
Cell Proliferation
Apoptosis
Gene Expression

Keywords

  • Angiogenesis
  • Xenograft mouse model

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. / Podar, Klaus; Tonon, Giovanni; Sattler, Martin; Tai, Yu Tsu; LeGouill, Steven; Yasui, Hiroshi; Ishitsuka, Kenji; Kumar, Shaji K; Kumar, Rakesh; Pandite, Lini N.; Hideshima, Teru; Chauhan, Dharminder; Anderson, Kenneth C.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 103, No. 51, 19.12.2006, p. 19478-19483.

Research output: Contribution to journalArticle

Podar, K, Tonon, G, Sattler, M, Tai, YT, LeGouill, S, Yasui, H, Ishitsuka, K, Kumar, SK, Kumar, R, Pandite, LN, Hideshima, T, Chauhan, D & Anderson, KC 2006, 'The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma', Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 51, pp. 19478-19483. https://doi.org/10.1073/pnas.0609329103
Podar, Klaus ; Tonon, Giovanni ; Sattler, Martin ; Tai, Yu Tsu ; LeGouill, Steven ; Yasui, Hiroshi ; Ishitsuka, Kenji ; Kumar, Shaji K ; Kumar, Rakesh ; Pandite, Lini N. ; Hideshima, Teru ; Chauhan, Dharminder ; Anderson, Kenneth C. / The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. In: Proceedings of the National Academy of Sciences of the United States of America. 2006 ; Vol. 103, No. 51. pp. 19478-19483.
@article{6139bdebf5a54880a6f245008b2fc2e5,
title = "The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma",
abstract = "A critical role for vascular endothelial factor (VEGF) has been demonstrated in multiple myeloma (MM) pathogenesis. Here, we characterized the effect of the small-molecule VEGF receptor inhibitor pazopanib on MM cells in the bone marrow milieu. Pazopanib inhibits VEGF-triggered signaling pathways in both tumor and endothelial cells, thereby blocking in vitro MM cell growth, survival, and migration, and inhibits VEGF-induced up-regulation of adhesion molecules on both endothelial and tumor cells, thereby abrogating endothelial cell-MM cell binding and associated cell proliferation. We show that pazopanib is the first-in-class VEGF receptor inhibitor to inhibit in vivo tumor cell growth associated with increased MM cell apoptosis, decreased angiogenesis, and prolonged survival in a mouse xenograft model of human MM. Low-dose pazopanib demonstrates synergistic cytotoxicity with conventional (melphalan) and novel (bortezomib and immunomodulatory drugs) therapies. Finally, gene expression and signaling network analysis show transcriptional changes of several cancer-related genes, in particular c-Myc. Using siRNA, we confirm the role of c-Myc in VEGF production and secretion, as well as angiogenasis. These preclinical studies provide the rationale for clinical evaluation of pazopanib, alone and in combination with conventional and novel therapies, to increase efficacy, overcome drug resistance, reduce toxicity, and improve patient outcome in MM.",
keywords = "Angiogenesis, Xenograft mouse model",
author = "Klaus Podar and Giovanni Tonon and Martin Sattler and Tai, {Yu Tsu} and Steven LeGouill and Hiroshi Yasui and Kenji Ishitsuka and Kumar, {Shaji K} and Rakesh Kumar and Pandite, {Lini N.} and Teru Hideshima and Dharminder Chauhan and Anderson, {Kenneth C.}",
year = "2006",
month = "12",
day = "19",
doi = "10.1073/pnas.0609329103",
language = "English (US)",
volume = "103",
pages = "19478--19483",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "51",

}

TY - JOUR

T1 - The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma

AU - Podar, Klaus

AU - Tonon, Giovanni

AU - Sattler, Martin

AU - Tai, Yu Tsu

AU - LeGouill, Steven

AU - Yasui, Hiroshi

AU - Ishitsuka, Kenji

AU - Kumar, Shaji K

AU - Kumar, Rakesh

AU - Pandite, Lini N.

AU - Hideshima, Teru

AU - Chauhan, Dharminder

AU - Anderson, Kenneth C.

PY - 2006/12/19

Y1 - 2006/12/19

N2 - A critical role for vascular endothelial factor (VEGF) has been demonstrated in multiple myeloma (MM) pathogenesis. Here, we characterized the effect of the small-molecule VEGF receptor inhibitor pazopanib on MM cells in the bone marrow milieu. Pazopanib inhibits VEGF-triggered signaling pathways in both tumor and endothelial cells, thereby blocking in vitro MM cell growth, survival, and migration, and inhibits VEGF-induced up-regulation of adhesion molecules on both endothelial and tumor cells, thereby abrogating endothelial cell-MM cell binding and associated cell proliferation. We show that pazopanib is the first-in-class VEGF receptor inhibitor to inhibit in vivo tumor cell growth associated with increased MM cell apoptosis, decreased angiogenesis, and prolonged survival in a mouse xenograft model of human MM. Low-dose pazopanib demonstrates synergistic cytotoxicity with conventional (melphalan) and novel (bortezomib and immunomodulatory drugs) therapies. Finally, gene expression and signaling network analysis show transcriptional changes of several cancer-related genes, in particular c-Myc. Using siRNA, we confirm the role of c-Myc in VEGF production and secretion, as well as angiogenasis. These preclinical studies provide the rationale for clinical evaluation of pazopanib, alone and in combination with conventional and novel therapies, to increase efficacy, overcome drug resistance, reduce toxicity, and improve patient outcome in MM.

AB - A critical role for vascular endothelial factor (VEGF) has been demonstrated in multiple myeloma (MM) pathogenesis. Here, we characterized the effect of the small-molecule VEGF receptor inhibitor pazopanib on MM cells in the bone marrow milieu. Pazopanib inhibits VEGF-triggered signaling pathways in both tumor and endothelial cells, thereby blocking in vitro MM cell growth, survival, and migration, and inhibits VEGF-induced up-regulation of adhesion molecules on both endothelial and tumor cells, thereby abrogating endothelial cell-MM cell binding and associated cell proliferation. We show that pazopanib is the first-in-class VEGF receptor inhibitor to inhibit in vivo tumor cell growth associated with increased MM cell apoptosis, decreased angiogenesis, and prolonged survival in a mouse xenograft model of human MM. Low-dose pazopanib demonstrates synergistic cytotoxicity with conventional (melphalan) and novel (bortezomib and immunomodulatory drugs) therapies. Finally, gene expression and signaling network analysis show transcriptional changes of several cancer-related genes, in particular c-Myc. Using siRNA, we confirm the role of c-Myc in VEGF production and secretion, as well as angiogenasis. These preclinical studies provide the rationale for clinical evaluation of pazopanib, alone and in combination with conventional and novel therapies, to increase efficacy, overcome drug resistance, reduce toxicity, and improve patient outcome in MM.

KW - Angiogenesis

KW - Xenograft mouse model

UR - http://www.scopus.com/inward/record.url?scp=33845882259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845882259&partnerID=8YFLogxK

U2 - 10.1073/pnas.0609329103

DO - 10.1073/pnas.0609329103

M3 - Article

C2 - 17164332

AN - SCOPUS:33845882259

VL - 103

SP - 19478

EP - 19483

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 51

ER -